NCT05579548 - A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

October 4, 2032

Study Completion Date

October 4, 2032

Conditions

Phenylketonuria, Maternal

Interventions

DRUG

Pegvaliase

Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.

Trial Locations (3)

NOT_YET_RECRUITING

Ospedale San Paolo, Milan

NOT_YET_RECRUITING

Universitaetsklinikum Hamburg Eppendorf, Hamburg

RECRUITING

Syneos Health, Wilmington